A pharmaceutical organization who was preparing for several global phase III studies of an orphan drug had 3 similar protocols underway simultaneously. Unfortunately, an error occurred in the specifications provided, which presented a challenge for safeguarding the integrity of the data and their ability to reduce the risk to their drug supply.
This insightful case study will show you how you can achieve the following:
- Provide greater visibility and reduce risk by integrating the physical and digital supply chains
- Give firmer control of quality processes via a comprehensive supply chain ecosystem
- Easily increase cost savings and avoidance of delays involved in reprogramming key systems
Submit the form on this page to automatically download case study or if you have a specific query regarding Almac ONE™, you can contact us directly.